Fatty liver disease (MASLD/MASH): open trials in Austria

9 open trials have a site in Austria. Registry data; only the trial team decides who can take part.

NCT07914829
Personalized Dietary Feedback to Reduce Hepatic Steatosis in Patients With MASLD
Trial Treatment · Medical University of Vienna
Medical University of Vienna, Vienna
Registry updated 2026-11-04
NCT06632444
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
Trial Treatment · Phase 3 · Boehringer Ingelheim
Medical University of Graz, Graz · Ordensklinikum Linz GmbH, Linz · Klinik Hietzing, Vienna · Klinik Landstrasse, Vienna · Medical University of Vienna, Vienna · Klinikum Wels-Grieskirchen GmbH, Wels
Registry updated 2026-10-28
NCT06632457
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
Trial Treatment · Phase 3 · Boehringer Ingelheim
Medical University of Graz, Graz · Ordensklinikum Linz GmbH, Linz · Allgemeines Krankenhaus Der Stadt Wien Universitatskliniken, Vienna · Klinik Hietzing, Vienna · Klinikum Wels-Grieskirchen GmbH, Wels
Registry updated 2026-10-28
NCT06318169
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Trial Treatment · Phase 3 · Hoffmann-La Roche
Medical University of Graz, Graz · Medizinische Universitaet Innsbruck, Innsbruck · Landeskrankenanstalten-Betriebsgesellschaft Kabeg, Klagenfurt Am Woerthersee · Noe LGA Gesundheit Region Mitte GmbH, St. Poelten · Klinikum Wels-Grieskirchen GmbH, Wels
Registry updated 2026-10-23
2026-525755-82-00
A pivotal clinical study to investigate the safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis due to Metabolic dysfunction-associated steatohepatitis (MASH)
Trial Treatment · Phase 3 · Glaxosmithkline Research & Development Limited
Medical University of Graz, Graz · Landeskrankenanstalten-Betriebsgesellschaft Kabeg, Klagenfurt Am Woerthersee · Medical University of Vienna, Vienna · Klinik Hietzing, Vienna
Registry updated 2026-10-19
2026-525757-37-00
A study to investigate safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis (stage F4 fibrosis) due to MASH (NEBULA-2)
Trial Treatment · Phase 3 · Glaxosmithkline Research & Development Limited
Medical University of Graz, Graz · Landeskrankenanstalten-Betriebsgesellschaft Kabeg, Klagenfurt Am Woerthersee · Medical University of Vienna, Vienna
Registry updated 2026-10-19
NCT07165028
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Trial Treatment · Phase 3 · Eli Lilly and Company
Medizinische Universität Graz, Graz · Uniklinikum Salzburg, Salzburg · Medizinische Universität Wien, Vienna · Klinik Landstraße, Vienna · Landesklinikum Wiener Neustadt, Wiener Neustadt
Registry updated 2026-10-08
NCT07221188
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
Trial Treatment · Phase 3 · GlaxoSmithKline
Medical University of Graz, Graz · Medizinische Universitaet Innsbruck, Innsbruck · Landeskrankenanstalten-Betriebsgesellschaft Kabeg, Klagenfurt Am Woerthersee · Klinik Hietzing, Vienna · Medical University of Vienna, Vienna
Registry updated 2026-09-17
NCT03811236
Cold-induced Brown Fat Activation and Hepatic Steatosis
Trial Treatment · Medical University of Vienna
Medical University of Vienna, Vienna
Registry updated 2024-03-13

All Fatty liver disease (MASLD/MASH) trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error